Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adherex Technologies, Inc.
Adherex executes trial agreement for ADH-1 with the U.S. National Cancer Institute
May 8th, 2006
Adherex Technologies, Inc., (ADH, AHX) a biopharmaceutical company with a broad portfolio of oncology products under development, announced that the company and the U.S. National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis have executed a Clinical Trial Agreement (CTA) for the evaluation of Adherex's lead biotechnology compound ADH-1. The agreement provides for the NCI to sponsor non-clinical studies and clinical trials of ADH-1 in a variety of administration schedules and tumor types, both as a single agent and in combination with other anticancer agents. "Through this agreement, we can move forward with our collaboration...
Source: Biotech Week (2006-05-08)
|
